伊布替尼联合利妥昔单抗治疗慢性淋巴细胞白血病患者类固醇难治性及复发性自身免疫性血细胞减少症高度有效
这项多中心研究纳入50例慢性淋巴细胞白血病(CLL)合并类固醇难治或复发性自身免疫性溶血性贫血(AIHA)或纯红细胞再生障碍(PRCA)的患者,采用伊布替尼联合利妥昔单抗诱导、伊布替尼单药维持。诱导后34例(74%)达完全缓解、10例(21.7%)达部分缓解,血红蛋白正常中位时间85天。结论认为该方案是此类患者活跃的二线治疗选择。
要点
- 50例CLL合并类固醇难治或复发性AIHA/PRCA患者接受伊布替尼联合利妥昔单抗治疗
- 诱导后34例(74%)达完全缓解、10例(21.7%)达部分缓解,血红蛋白正常中位时间85天
- 最常见不良事件为感染(72%)、中性粒细胞减少(62%)和胃肠道并发症(54%)
核心结论
- 伊布替尼联合利妥昔单抗是CLL合并复发性或难治性AIHA/PRCA患者的活跃二线治疗选择。
研究设计与样本
- 多中心研究,纳入50例CLL合并类固醇难治或复发性AIHA/PRCA患者,其中44例温抗体型AIHA、2例冷抗体型AIHA、4例PRCA。
- 方案包括诱导期(伊布替尼420 mg/日联合利妥昔单抗,8次每周输注及4次每月输注)和维持期(伊布替尼单药直至疾病进展或不可接受毒性)。
主要发现
- 诱导后34例(74%)达完全缓解,10例(21.7%)达部分缓解,血红蛋白正常中位时间85天。
- CLL疗效方面,9例(19%)达完全缓解,2例(4%)达疾病稳定,39例(78%)达部分缓解。
- 中位随访37.56个月,AIHA组2例复发;PRCA组4例中1例无应答、1例完全缓解后复发、2例维持完全缓解。
- 最常见不良事件为中性粒细胞减少(62%)、感染(72%)和胃肠道并发症(54%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autoimmune hemolytic anemia (AIHA) and pure red cell aplasia (PRCA) are common complications of CLL. The optimal treatment of steroid refractory AIHA/PRCA is not well established. We conducted a multicenter study of ibrutinib and rituximab in patients with relapsed/refractory to steroids AIHA/PRCA and underlying CLL. Protocol included induction (ibrutinib 420 mg/day and rituximab, 8 weekly and 4 monthly infusions) and maintenance phase with ibrutinib alone until progression or unacceptable toxicity. Fifty patients were recruited (44-warm AIHA, 2-cold AIHA, 4-PRCA). After the induction 34 patients (74%) have achieved complete response, 10 (21.7%) partial response. Median time to hemoglobin normalization was 85 days. With regards to CLL response 9 (19%) patients have achieved CR, 2 (4%) patients-stabilization and 39 (78%)-PR. The median follow-up was 37.56 months. In AIHA group 2 patients had a relapse. Among 4 patients with PRCA 1 patient did not respond, and 1 patient had a relapse after CR, 2 remained in CR. The most common adverse events were neutropenia (62%), infections (72%), gastrointestinal complications (54%). In conclusion ibrutinib in combination with rituximab is an active second-line treatment option for patients with relapsed or refractory AIHA/PRCA and underlying CLL.
引用
- Nikitin E, Kislova M, Morozov D, et al. Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias. Leukemia. 2023. PMID: 37202442. doi:10.1038/s41375-023-01891-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。